Bioatla

Bioatla Liabilities

The The Liabilities of Bioatla (BCAB) as of Nov 18, 2026 is 50.02 M USD. In the previous year, The Liabilities was 38.16 M USD — a change of 31.08% (higher).

Liabilities

50.02 MUSD

YoY

31.08%

Last updated:

In 2025, Bioatla's total liabilities amounted to 50.02 M USD, a 31.08% difference from the 38.16 M USD total liabilities in the previous year.

The Bioatla Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
45.08 M USD
Jan 1, 2019
65.35 M USD
Jan 1, 2020
34.96 M USD
Jan 1, 2021
43.60 M USD
Jan 1, 2022
45.40 M USD
Jan 1, 2023
48.99 M USD
Jan 1, 2024
38.16 M USD
Jan 1, 2025
50.02 M USD
The Bioatla Liabilities history
YEARLiabilitiesYoY
50.02 MUSD+31.08%
38.16 MUSD-22.11%
48.99 MUSD+7.91%
45.40 MUSD+4.12%
43.60 MUSD+24.71%
34.96 MUSD-46.50%
65.35 MUSD+44.95%
45.08 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioatla Stock analysis

What does Bioatla do? BioAtla develops antibody-based therapeutics for solid tumor cancer, focusing on conditionally active biologics (CAB) antibody-drug conjugates (ADCs). Its lead product BA3011 targets AXL, a protein kinase receptor, while BA3021 targets ROR2, a receptor tyrosine kinase. BA3071 is a CAB anti-CTLA-4 antibody for multiple solid tumors including renal cell carcinoma and melanoma, and BA3182 uses Dual-CAB technology for adenocarcinoma treatment. The company generates revenue through the development and commercialization of these product candidates, targeting oncology treatment markets with specific therapeutic approaches. BioAtla's product pipeline includes BA3011, BA3021, BA3071, and BA3182, each addressing distinct cancer targets. The company focuses on developing novel therapeutics rather than selling existing products, with BA3011 as its lead candidate. Revenue is expected from future partnerships, licensing agreements, or eventual product sales once clinical development progresses to later stages. The company's business model centers on advancing its pipeline through clinical trials, with potential revenue streams from biopharmaceutical partnerships and product launches. BA3071 targets multiple solid tumor indications, including NSCLC and hepatocellular carcinoma, while BA3182 is designed for advanced adenocarcinoma. BioAtla's focus on CAB technology differentiates its approach in the oncology space. Bioatla is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Bioatla's Liabilities

Bioatla's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Bioatla's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Bioatla's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Bioatla's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Bioatla’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Bioatla stock

The Liabilities of Bioatla is 50.02 M USD in 2025.

The Liabilities of Bioatla changed from 38.16 M USD to 50.02 M USD, representing a 31.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Bioatla since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Bioatla historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Bioatla

All Key Metrics — Bioatla